Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03391440
Other study ID # HS-10090-401
Secondary ID
Status Recruiting
Phase Phase 4
First received November 28, 2017
Last updated December 29, 2017
Start date September 2016
Est. completion date December 2018

Study information

Verified date November 2017
Source Jiangsu Hansoh Pharmaceutical Co., Ltd.
Contact Shixuan Wang
Phone 02783663078
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the efficacy, safety and Population Pharmacokinetic (PPK) of morinidazole and sodium chloride injection with levofloxacin hydrochloride and sodium chloride injection sequential of levofloxacin hydrochloride tablets in women with pelvic inflammatory disease: An Open-Lable Multicenter Prospective Non-Randomized Trial


Description:

Pelvic inflammatory disease (PID) is a spectrum of upper genital tract inflammations comprising endometritis, salpingitis, parametritis, oophoritis, tubo-ovarian abscess and/or pelvic peritonitis. The objectives of administering antimicrobial therapy in patients with PID are to control the symptoms and to prevent the late sequelae of the disease. Because anaerobe infections (e.g., Bacteroides fragilis infections) are associated with tubal and epithelial damage, anaerobic coverage is routinely recommended in women with pelvic infection. Guidelines have been developed in both the USA and Europe with regard to PID management. Metronidazole, a member of the nitroimidazole drug class, is included in the regimens recommended for improving anaerobic bacteria coverage. The sideeffects of metronidazole include a metallic taste, nausea, transient neutropenia, and peripheral neuropathy. Antimicrobial resistance to metronidazole has emerged after several decades of worldwide use of the drug. Morinidazole, a National Class I Antimicrobial, is a new type of third-generation nitroimidazole antimicrobial that is used for treating amoebiasis, trichomoniasis, and anaerobic bacterial infections, and which exhibits greater activity and less toxicity than metronidazole.

Morinidazole and Sodium Chloride Injection used in PID or appendicitis cases had been approved by CFDA in 2014. This phase 4 study is to assess the efficacy, safety and Population Pharmacokinetic (PPK) of morinidazole in PID.


Recruitment information / eligibility

Status Recruiting
Enrollment 469
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- women between 18 and 65 years old

- patients with the diagnosis of PID:

1. sexually active women or women have the risk of sexually transmitted infections, and

2. lower abdominal pain symptoms, and

3. lower abdominal tenderness, and adnexal and cervical motion tenderness on bimanual vaginal examination, and

4. as well as at least one of the following signs:

1. pyrexia (axillary temperature > 37.8 °C)

2. mucopurulent cervical or vaginal discharge

3. an elevated vaginal discharge white blood cell count (WBC)

4. an elevated erythrocyte sedimentation rate

5. an elevated C-reactive protein

6. laboratory tests confirmed the presence of Chlamydia trachomatis infection in the cervix

7. WBC > 10*109/L on routine blood examination

5. Voluntary signing of written informed consent

Exclusion Criteria:

- patients with a history of antibiotic therapy for more than 3 days

- patients with any condition likely to require surgery

- Cervical / vaginal discharge examination found Gonorrhea gonorrhea

- patients with an allergy to nitroimidazole or quinolones

- patients with brain and spinal cord lesions, epilepsy and various organ sclerosis

- patients who received an abortion or surgery of uterus, cervix, abdomen within 1 month

- serious chronic liver disease (Child-Pugh graded C-class)

- patients with hematopoietic dysfunction or chronic alcoholism

- any factors that increase the risk of QTc prolongation or arrhythmia

- ALT and / or AST = 2 times the ULN

- serum creatinine = 1.5 times the ULN

- total bilirubin = 1.5 times the ULN

- ECG QTc interval> 470ms

- any clinically significant abnormalities in rhythms, conduction or morphology of resting ECGs

- Pregnant women, breastfeeding women, women of childbearing age without effective contraceptive

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
morinidazole
morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)

Locations

Country Name City State
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical cure Rate Clinical cure Rate (according to symptoms and signs) at 7-30 days post-therapy 7-30 days
Secondary The incidence of AE The incidence of adverse events 14 days
Secondary Incidence of ADR Incidence of adverse reactions 14 days
Secondary Incidence of serious ADR Incidence of serious adverse reactions 14 days
Secondary Bacteriological response(Bacterial elimination rate) Bacteriological response (on the first day post-therapy, at 7-30 days post-therapy) the first day and 7-30 days
Secondary PPK parameters Area under the plasma concentration versus time curve (AUC) of morinidazole 14 days
See also
  Status Clinical Trial Phase
Completed NCT04723069 - Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases Phase 2
Completed NCT01671280 - Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan) N/A
Completed NCT00115388 - Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease N/A
Not yet recruiting NCT02972151 - Clinical Research of TCM on Pelvic Inflammatory Disease Sequelae Phase 2
Completed NCT01160640 - The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID) Phase 2
Completed NCT01236131 - The Role of Novel Organisms in Acute Endometritis N/A
Active, not recruiting NCT03994055 - Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer N/A
Completed NCT00871494 - Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan Phase 3
Completed NCT00783419 - Rate of Pelvic Inflammatory Disease at St. Michael's Hospital
Completed NCT01799356 - Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials Phase 4
Recruiting NCT05408624 - Pilot Study Evaluating Outpatient Management of Tubo-ovarian Abscesses
Completed NCT01241110 - To Compare Ofloxacin With Azitromycin for Pelvic Inflammatory Disease (PID) Treatment Phase 4
Completed NCT00453349 - A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease Phase 3
Recruiting NCT04234945 - Effect of Prophylactic Antibiotics for Hysterosalpingography on Post Procedure Morbidity N/A
Recruiting NCT06360965 - Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain N/A
Recruiting NCT05648747 - Pelvic Inflammatory Disease in COVID-19 Era
Completed NCT01793584 - Surgical Success After Laparoscopic vs Abdominal Hysterectomy N/A
Completed NCT01299259 - Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease N/A
Completed NCT03054402 - First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845 Phase 1
Active, not recruiting NCT03828994 - Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID II N/A